biote 2025 Q2 Earnings Strong Performance as Net Income Surges 137.9%

biote (BTMD) reported its fiscal 2025 Q2 earnings on August 8, 2025, marking a notable financial turnaround. The company returned to profitability, with net income jumping from a loss of $10.37 million in Q2 2024 to $3.92 million in the same period this year. This represents a 137.9% positive swing and a record high for Q2 net income in four years.

Revenue

Total revenue for biote declined slightly by 0.6% to $48.86 million in 2025 Q2, compared to $49.17 million in 2024 Q2. Within the revenue breakdown, product revenue remained the largest component at $47.66 million, driven by $35.20 million in pellet procedures and $10.75 million in dietary supplements. Disposable trocars contributed $1.23 million, while shipping fees and other income totaled $474,000. Service revenue stood at $1.21 million, with training, contract-term services, and other categories adding $333,000, $338,000, and $535,000 respectively.

Earnings/Net Income

The company's turnaround was also reflected in its EPS, which rose to $0.10 in Q2 2025 from a loss of $0.21 in Q2 2024, representing a 147.6% improvement. The robust net income performance highlights biote's improved operational efficiency and cost management, underscoring its ability to execute its strategic vision effectively.

Price Action

Following the earnings report, biote's stock price experienced a sharp decline, dropping 3.03% on the latest trading day. The downward trend continued as the stock plunged 25.96% during the most recent full trading week and 30.10% month-to-date.

Post-Earnings Price Action Review

The historical strategy of purchasing BTMD shares after a quarter with positive revenue growth on the earnings report date and holding for 30 days has proven to deliver moderate returns but underperform the market. With a CAGR of 4.19% and a maximum drawdown of 0.00%, the strategy has shown low risk but modest gains. Its Sharpe ratio of 0.06 indicates a conservative approach suitable for investors seeking stability.

CEO Commentary

Marc Beer, Executive Chairman of Biote, emphasized the strategic importance of newly appointed board member Rich Barrera, highlighting his investment expertise and long-term vision. Beer noted that Barrera’s insights in portfolio management and corporate governance align with Biote’s growth strategy and expressed confidence in the company’s ability to drive long-term value creation.

Guidance

Biote did not provide specific quantitative guidance for the period under review. However, the company remains focused on expanding practitioner adoption of the Biote Method and enhancing market acceptance of its hormone optimization solutions. It anticipates continued alignment with institutional shareholders and aims to strengthen long-term value creation.

Additional News

Recent developments in the financial and business sectors include discussions around corporate governance and strategic partnerships. Notably, C-level changes have seen increased focus on long-term shareholder value and boardroom expertise. While no direct acquisitions or buybacks were reported for biote in the immediate period following its earnings report, broader industry trends highlight the importance of strategic board appointments and institutional alignment in driving corporate growth.